Mats Wahlström has served as Chairman of the board of directors of TriSalus since January 2017. Mats has also served as the Co-Chairman of HW Investment Partners, LLC since July 2016 and as Partner and Executive Chairman of KMG Capital Partners, LLC since April 2012, both investment funds focused on investments in the healthcare industry.

In addition, Mats has served as the Chairman of the board of directors of Triomed AB since October 2016, as the lead independent director of Coherus Biosciences, Inc., a public biotech company, since January 2012 and as Chairman of Caduceus Medical Holdings, Inc. since August 2010. Mats has served on the boards of directors of Alteco Medical AB since October 2012, Circuit Clinical Solutions, Inc. since July 2016 and PCI | HealthDev since August 2010. He served as a director of Health Grades, Inc. a Nasdaq-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in October 2010, as a director of Getinge AB, a Swedish Stock Exchange-listed medical device company, from March 2012 to March 2017, and as a director of Zynex Inc. an over-the-counter medical device manufacturer, from October 2010 through January 2014. From January 2004 to December 2009, Mats served as co-CEO of Fresenius Medical Care North America and a member of the management board at Fresenius Medical Care AG & Co. KGaA. From November 2002 to December 2009, Mats served as President and Chief Executive Officer of Fresenius Medical Services. Prior to that, Mats held various positions at Gambro AB in Sweden from January 1983 to February 2000, including President of Gambro North America and Chief Executive Officer of Gambro Healthcare Inc. as well as Chief Financial Officer of the Gambro Group.

Mats has a B.S. degree in Economics and Business Administration from the University of Lund, Sweden.

Kerry has served as Partner, Chief Executive Officer, and President of KMG Capital Partners LLC, a boutique healthcare venture capital company, since April 2012. He also currently serves as Executive Chairman of Circuit Clinical, an integrated research organization, and Co-Chairman and Partner of HW Investment Partners, LLC, a venture capital firm that focuses on investing in healthcare companies, both positions which he has held since 2016.

Prior to joining KMG Capital Partners, Kerry served as Chief Executive Officer of Healthgrades, a healthcare information and services company, from 2000 to 2012, Chairman of Healthgrades from 2000 to 2010 and 2012 to 2013, and as President, Chief Executive Officer and Chairman of Specialty Care Network, a predecessor company to Healthgrades, from 1995 to 2000. Mr. Hicks has been a member of the board of directors of TriSalus since April 2021.

Kerry received his B.S. degree in Management and his MBA in Business Administration from Colorado State University.

Sean Murphy was appointment Chief Manufacturing, Strategy and Business Development Officer in January 2025. Previously he served as CFO of TriSalus since June 2022. Sean has also been a director of TriSalus since August 2020 and served as the chairman of the audit committee from August 2020 through June 2022.

Previously, Sean served as Executive Vice President at Malin PLC, a publicly listed company investing in life sciences companies, from April 2016 through June 2021. Sean was a senior advisor at Evercore, an independent investment banking advisory firm, from August 2011 to June 2018. Prior to that, he held numerous positions over a 30-year career with Abbott Laboratories, a multinational medical devices and health care company, culminating as Vice President of Business Development and Licensing. Sean has had extensive Board experience as well. He currently serves on the boards of directors of Immucor, Xenex, and Prenosis. In addition, Sean previously served on the public company board of directors of Radius Health, where he sat on the audit committee, and Poseida, where he was a member of the compensation and governance committee.

Sean received his BBA in Finance and Accounting from Western Illinois University and his M.S. in Finance from University of Illinois. He is a Certified Public Accountant, State of Illinois.

Mary Szela has nearly 35 years of experience driving growth and creating value for patients and investors in both the commercial and clinical pharmaceutical arenas.

Mary has served as CEO and President of TriSalus Life Sciences since January 2018. Prior to joining TriSalus, Mary served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she led the company through regulatory compliance and legal difficulties, ultimately orchestrating a successful merger and expansion of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company’s revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus).

Previously, Mary held progressive leadership roles at Abbott Laboratories including President of the company’s $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Senior Vice President for global strategic marketing and services.

Mary currently serves as a member of the Board of Directors for Kura Oncology, Prometheus Biosciences, Omega Therapeutics and Senda Biosciences. She received both her B.S. in Nursing and her MBA from the University of Illinois at Chicago.

Dr. Andrew von Eschenbach is the President and founder of Samaritan Health Initiatives, Inc., a health care policy consultancy, a role which he has held since 2010. He is also an Adjunct Professor at the University of Texas M.D. Anderson Cancer Center (“MDACC”), a position he has held since 2009.

Dr. von Eschenbach holds advisory roles as the Senior Advisor at Target RWE, a biotechnology company, since September 2020, and Medical Advisor at Datavant, a health information technology company, since January 2020. From October 2017 to June 2019, Dr. von Eschenbach served as Chief Medical Advisor at Malin Corporation PLC, a life sciences company. From 2009 to 2021, he worked on the International Advisory Council of Chugai Pharmaceutical Co., Ltd., a Japanese drug manufacturer. From 2012 to 2016, Dr. von Eschenbach was a Senior Fellow and Director of the FDA Project at the Manhattan Institute, a think tank. From 2009 to 2018, he served on the GE Healthymagination Advisory Board, a GE Healthcare initiative to provide better healthcare for more people around the world. From 2012 to 2016, he served as a global council member of Eli Lilly and Company, PACE, a global collaboration that encourages public policies and healthcare decisions that speed the development of new medicines. From September 2005 to January 2009, Dr. von Eschenbach served as Commissioner of the FDA. Previously, Dr. von Eschenbach served as Director of the National Cancer Institute at the National Institutes of Health from January 2002 to June 2006. As a researcher, clinician and administrator, Dr. von Eschenbach served in a variety of roles at MDACC, including as Director, Genitourinary Cancer Center, Vice President for Academic Affairs, and Executive Vice President and Chief Academic Officer. Dr. von Eschenbach currently serves on the boards of directors of Bausch and Lomb Corporation and Celularity, Inc. In addition, Dr. von Eschenbach previously served on the boards of directors of Bausch Health Companies and Radius Health, Inc.

Dr. von Eschenbach received his B.S. in biology from St. Joseph’s University and his M.D. in medicine from Georgetown University.

David served as the Chief Financial Officer and director of MTAC’s since September 2020. David was also the co-founder and Chief Executive Officer of MatlinPatterson Global Advisers LLC (“MatlinPatterson”), a distressed securities investment manager, which he co-founded in July 2002, through 2021.

David was also Chief Executive Officer of MatlinPatterson Asset Management L.P. and its operating joint venture affiliates that managed non-distressed credit strategies, from 2015 to 2018. In 2017, MatlinPatterson began winding down its investment activities and its various funds began to return the investment proceeds to their respective investors. In conjunction with this wind-down process and to protect their investors from foreign litigation, two of the MatlinPatterson funds (Matlin Global Opportunities Partners II L.P. and Matlin Global Opportunities Partners (Cayman) II L.P.) that had been unable to settle foreign litigation, filed, along with MatlinPatterson, voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in July 2021. Prior to forming MatlinPatterson, David was a Managing Director at Credit Suisse, and headed their Global Distressed Securities Group upon its inception in 1994. David was also a Managing Director and a founding partner of Merrion Group, L.P., an investment advisory firm, from 1988 to 1994.

He began his career as a securities analyst at Halcyon Investments from 1986 to 1988. Until its November 2022 sale, David also served on the board of directors of US Well Services Inc. (Nasdaq: USWS) (formerly Matlin & Partners Acquisition Corporation) and was Chief Executive Officer and Chairman of the company prior to its business combination with US Well Services LLC. He also serves on the boards of directors of Dermasensor, Inc. and Pristine Surgical LLC, which are medical device manufacturers. David has served on the board of directors of Clene, Inc. (Nasdaq: CLNN), a biopharmaceutical manufacturer, since December 2020, and has served as the Chairman of its Board of Directors since May 2021. Since 2020, he has served on the board of Traffk, LLC, an insurance-based data analytics company, and since July 2021, he has served on the board of Empyrean Neuroscience, a biotechnology company. Previously, he served on the board of directors of Flagstar Bank FSB, a federally charted savings bank, and Flagstar Bancorp, Inc. (NYSE: FBC), a savings and loan holding company from 2009 to May 2021, CalAtlantic Group, Inc. (NYSE: CAA), a U.S. homebuilder, from 2009 to 2018, Global Aviation Holdings, Inc., an air charter company, from 2006 to 2012, and Huntsman Corporation (NYSE: HUN), a U.S. chemicals manufacturer, between 2005 and 2007 and Orthosensor, Inc. until the sale of the company to Stryker Corporation in December 2020.

David holds a JD degree from the Law School of the University of California at Los Angeles and a BS in Economics from the Wharton School of the University of Pennsylvania.

Dr. Arjun Desai has served as the Chief Strategic Innovation Officer at Insightec, a medical device company, since 2018.

Previously, from 2016 to 2018, Dr. Desai served as the Global Vice President and Chief Operating Officer of Johnson & Johnson Innovation, a company that collaborates with innovators to incorporate science into healthcare solutions. Additionally, Dr. Desai currently serves on the boards of directors of Obvius Robotics, Inc., Tympa Health TechnologiesLtd, Pathology Watch, Openwater Software, Inc., and Wesper.

Dr. Desai received his B.S. degree in Economics from the University of Oklahoma and his M.D. from the University of Miami. He also completed his residency and advanced training in Anesthesiology at Stanford University.

William “Bill” Valle is the Executive Chairman of Compassus, a leading provider of hospice, home health, palliative, and infusion services, and serves on the board of directors of American Oncology Network, a community-based oncology company. He has held both roles since 2024 following his retirement from Fresenius Medical Care.

Previously, Bill was Chief Executive Officer of Care Delivery at Fresenius Medical Care AG (2022-2023) and CEO of Fresenius Medical Care North America (2017-2022). He also served on the company’s management board (2017-2023) and held leadership roles as Co-Executive Chair of Interwell Health, an at-risk kidney care management company, and as a director of multiple Fresenius subsidiaries, including Fresenius Medical Care U.S. Finance II.

From 2013 to 2016, Bill was Executive Vice President and President of Fresenius Kidney Care, overseeing its core renal services. Before that, he led the integration of key business functions, including Azura Vascular Care, Fresenius RX, Spectra Laboratories, and Business Development into a high-performing renal network aimed at improving patient outcomes and reducing costs.

Earlier in his career, Bill spent seven years as President of Innovative Health Strategies, LLC, a healthcare consulting firm, and 12 years at Gambro Healthcare, Inc., where he held leadership roles in sales management, marketing, and business development.

With decades of experience in healthcare leadership, Bill Valle has played a significant role in shaping patient-centered, cost-effective care models across multiple sectors.

An accomplished pharmaceutical executive and strategic business leader, Dr. Gordon has extensive experience in the development of drugs from first in-human studies to approval and commercialization.

Dr. Gordon brings innovative approaches to the process, leveraging advantageous regulatory pathways and close collaborations with investigators, patient advocacy groups and key academic and government consortiums.

Prior to joining GCAR, Dr. Gordon served as Vice President, Oncology Department at AbbVie (a spin-off of Abbott), where he oversaw the development of AbbVie’s oncology projects. He played a critical role in the oncology business expansion, leading to AbbVie’s current position in Oncology. This includes the approval of venetoclax, several major acquisitions and other collaborations. Dr. Gordon was on the AbbVie-Genentech team that received the 2017 Prix Galien award for the Best Pharmaceutical Product.

Prior to AbbVie, Dr. Gordon was Chief Scientific Officer and Vice President of Clinical Affairs at Ovation Pharmaceuticals from 2001 to 2003.

Dr. Gordon entered the pharmaceutical industry in 1995, joining the G.D. Searle division of Monsanto, which eventually became part of Pharmacia.